Lorlatinib 100mg

COMPOSITION:

EACH LUCILAROTREC CAPSULE CONTAINS: Larotrectinib sulfate 123mg equivalent to Larotrectinib ………… 100mg

INDICATION:

LuciLarotrec is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that:

Have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.

DOSAGE AND USE:

• Recommended Dosage in Adult and Pediatric Patients with Body Surface Area of at Least 1.0 Meter-Squared: 100 mg orally twice daily.
• Recommended Dosage in Pediatric Patients with Body Surface Area of Less Than 1.0 Meter- Squared: 100 mg/m2 orally twice daily.

Tablets/Capsules should be swallowed whole & not chewed or crushed.

STORAGE:

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).

Keep medicine out of the reach of Children.

Manufactured and Marketed by: LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING AND PRECAUTION:

To be sold by retail on prescription of a Registered oncologist only, and as directed by the physician.